Post by
Noteable on Aug 16, 2022 10:17am
AstraZeneca paid USD$ 5.5 Billion to co-market Enhertu
March 2019 - AstraZeneca entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201) (Enhertu), a proprietary antibody-drug conjugate (ADC) a targeted medicine for cancer treatment.
Under the terms of the agreement, AstraZeneca paid Daiichi Sankyo an upfront payment of $1.35bn.
Comment by
westcoast1000 on Aug 28, 2022 5:46pm
Noteable, Thanks for this helpful insight on ONCY and CAR-T potential. This is another exciting prospect for ONCY.